The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

Saultz and Lochner’s research have long highlighted how relational continuity enhances trust, communication, and shared ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapeutics CEO Paul Romness and EVERSANA VP of ...

The FDA has a new director for the Center for Drug Evaluation and Research (CDER), with biopharma industry executive George ...

A once-daily tablet that can help people suffering from hay fever caused by birch tree pollen, Alk-Abelló's Itulazax, has ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

The UK government has revealed a plan to open a biosecurity facility in Harlow, Essex, to help protect the country from ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...